Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib

Fabio Stagno, Alessandra Cupri, Stefania Stella, Michele Massimino, Silvia Rita Vitale, Paolo Vigneri



Imatinib mesylate (IM) has shown unprecedented effectiveness in the treatment of Chronic Myeloid Leukemia (CML) patients (pts) in the chronic phase of the disease. However, some pts fail to respond or lose their initial response to IM. The European LeukemiaNet (ELN) published recommendations designed to identify patients responding poorly to imatinib. Here we report a case of a suboptimal cytogenetic responder to IM who had a successful response to the second generation tyrosine kinase inhibitor nilotinib (NIL). According to the ELN criteria, CML pts on IM-therapy might show a suboptimal response either because of failure to achieve a CCyR by 12 months of therapy or because of lack of a MMR after 18 months. The prognostic value of these two types of responders might be very different.


Nilotinib; Chronic myeloid leukemia; Therapy; Tyrosine kinase inhibitors

Full Text



Abstract: 362 views
PDF: 257 views


  • There are currently no refbacks.